Predetermined Anti-Diabetic Drug Regimen Adjustments during Ramadan Fasting: An Observational Study of Safety

Endocrinology and Metabolism

Zaid H. Gheith¹  Mohammad A. Zmaili²  Ahmad M. Naser²  Abdallah M. Beano²  Ayman A. Zayed³  Munther S. Momani³  Al-Motassem F. Yousef⁴ 

[1] Department of Internal Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan.;Department of Internal Medicine, The University of Jordan School of Medicine, Amman, Jordan.;Division of Endocrinology and Metabolism, Department of Internal Medicine, Jordan University Hospital, The University of Jordan School of Medicine, Amman, Jordan.;The University of Jordan Faculty of Pharmacy, Amman, Jordan.;

关键词: Ramadan;    Hypoglycemia;    Sulfonylurea;    Metformin;    Insulin;   

DOI  :  10.3803/EnM.2017.32.2.265

来源: DOAJ

【 摘 要 】

BackgroundMany Muslim type 2 diabetes mellitus (T2DM) patients choose to fast the month of Ramadan despite the possible adverse health effects brought about by the change in dietary habits, among other things. Clinical data regarding the safety of multi-drug regimens during fasting are particularly scarce. The aim of the study was to evaluate the safety of a drug protocol devised by the authors to accommodate Ramadan's dietary changes, involving dose adjustments of four anti-diabetic drug regimens in T2DM patients fasting Ramadan.MethodsIn this prospective, observational, open-label study, 301 T2DM patients who wished to fast Ramadan were followed during Ramadan and the preceding month. The incidence of hypoglycemia, diabetic ketoacidosis (DKA) and non-ketotic hyperosmolar state (NKHS) was monitored. Patients were classified into four groups: A group (those taking metformin, sulfonylurea and insulin [n=33]); B group (metformin and sulfonylurea [n=89]); C group (metformin and insulin [n=96]); and D group (premixed 70/30, glargine or regular insulin [n=82]). During Ramadan, drug doses were adjusted as percentages of their pre-Ramadan values: 75% for sulfonylureas, 75% for glargine, 75% for premixed insulin 70/30 in two doses, and 75% for regular insulin. Metformin was adjusted to a twice-daily regimen.ResultsNo cases of DKA or NKHS were reported. Hypoglycemia occurred at a lower rate than pre-Ramadan values in groups C, and D; and a similar rate in groups A, and B.ConclusionThe data suggested that using the above protocol to adjust the doses of anti-diabetic drugs is safe in T2DM patients in regards to hypoglycemia, DKA, and NKHS.

【 授权许可】

Unknown